Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158

This article has now been updated. Please use the final version.

Quantitation of Oxidative Modifications of Commercial Human Albumin for Clinical Use: Thiol Oxidation and Carbonylation.
Teppei TakahashiTomoyoshi TeradaHajime ArikawaKazuha KizakiHiroyuki TerawakiHajime ImaiYoshinori ItohSeiichi Era
Author information
JOURNAL FREE ACCESS Advance online publication

Article ID: b15-00843

Details
Abstract

We investigated the quantitation of oxidative chemical modifications, such as thiol oxidation and carbonylation, in medical-grade HSA preparations, in comparison with those of healthy and diseased subjects. Four kinds of HSA products were obtained from three major suppliers in Japan. Eight male collegiate students and six healthy male volunteers were recruited as the young (21.6 years) and older (57.2 years) groups, respectively. Four male stable patients (64.3 years) treated with regular hemodialysis (HD) also enrolled in this study. Quantitative analyses for thiol oxidation and carbonylation were performed using HPLC and spectroscopic methods, respectively. Structural characterization was further investigated by differential scanning calorimetry (DSC) and circular dichroism (CD) spectropolarimetry. Significantly larger amounts of thiol-oxidized and carbonylated HSA products were observed than HSA obtained from healthy subjects. In the structural characterization, the midpoint temperature of the denaturation curve (Tm) analyzed by DSC was relatively high, and may have been caused by the added albumin-specific stabilizers, and CD-resolved secondary structure showed that HSA products had a helical conformation. Commercial HSA products for clinical use have a more thermally stable state and remain in a helix-rich structure, even though their specific amino acids (mainly Cys and Lys residues) are oxidatively modified.

Content from these authors
© 2015 The Pharmaceutical Society of Japan
feedback
Top